IGKV2D-29 and fragile X syndrome: In conclusion, although further studies are needed to clarify the cross-talk between A2A and mGlu5 receptors in the FXS condition, these findings suggest that A2AR antagonists could represent a possible novel therapeutic tool in FXS.